Colorectal Cancer Screening
Universal Diagnostics has developed an investigational blood-based test for colorectal cancer which is able to detect both pre-cancerous polyps and early stages of colorectal cancer. An investigational test is one that is not approved by the U.S. Food and Drug Administration (FDA). This test uses a blood sample otherwise known as a “liquid biopsy”. It is minimally invasive, quick, and is designed to assist doctors to detect, treat and monitor cancer in real-time.
This study is evaluating Universal Diagnostic’s blood-based test called Signal-Cä. It uses biomarkers in your blood for the detection of colorectal cancer and pre-cancerous lesions
The purpose of this study is to collect blood samples that can be used to test this device. You will not receive any results from the study device.
Up to $150
Are you eligible to participate?
45-84 years of Age
Intended to undergo a standard-of-care screening colonoscopy
Considered by a physician or healthcare provider as being of 'average risk' for CRC
Willing to consent to blood draw prior to bowel preparation and undergoing colonoscopy ideally within 90 days of the date of the investigational blood draw
Willing to consent to a follow-up phone call after one year
Able and willing to sign informed consent